- Home
- WWR vs CELU Comparison
WWR vs CELU Comparison
Compare WWR & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WWR
- CELU
- Stock Information
- Founded
- WWR 1977
- CELU 2016
- Country
- WWR United States
- CELU United States
- Employees
- WWR N/A
- CELU N/A
- Industry
- WWR Metal Mining
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- WWR Basic Materials
- CELU Health Care
- Exchange
- WWR Nasdaq
- CELU Nasdaq
- Market Cap
- WWR 48.0M
- CELU 42.2M
- IPO Year
- WWR N/A
- CELU N/A
- Fundamental
- Price
- WWR $0.79
- CELU $3.48
- Analyst Decision
- WWR Strong Buy
- CELU
- Analyst Count
- WWR 2
- CELU 0
- Target Price
- WWR $2.00
- CELU N/A
- AVG Volume (30 Days)
- WWR 2.1M
- CELU 143.3K
- Earning Date
- WWR 08-07-2025
- CELU 05-08-2025
- Dividend Yield
- WWR N/A
- CELU N/A
- EPS Growth
- WWR N/A
- CELU N/A
- EPS
- WWR N/A
- CELU N/A
- Revenue
- WWR N/A
- CELU $54,220,000.00
- Revenue This Year
- WWR N/A
- CELU $23.29
- Revenue Next Year
- WWR N/A
- CELU N/A
- P/E Ratio
- WWR N/A
- CELU N/A
- Revenue Growth
- WWR N/A
- CELU 138.11
- 52 Week Low
- WWR $0.45
- CELU $1.00
- 52 Week High
- WWR $1.32
- CELU $5.22
- Technical
- Relative Strength Index (RSI)
- WWR 57.08
- CELU 61.75
- Support Level
- WWR $0.65
- CELU $3.03
- Resistance Level
- WWR $0.79
- CELU $3.64
- Average True Range (ATR)
- WWR 0.06
- CELU 0.24
- MACD
- WWR -0.01
- CELU -0.02
- Stochastic Oscillator
- WWR 72.53
- CELU 75.25
About WWR Westwater Resources Inc.
Westwater Resources Inc focused on developing battery-grade natural graphite materials. The company is having one project which is the Westwater's coosa project which is currently used for the mining and extraction of graphite.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.